Cover Page
Cover Page - shares | 6 Months Ended | |
Jun. 30, 2024 | Jul. 26, 2024 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2024 | |
Document Transition Report | false | |
Entity File Number | 001-38672 | |
Entity Registrant Name | ARVINAS, INC. | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 47-2566120 | |
Entity Address, Address Line One | 5 Science Park | |
Entity Address, Address Line Two | 395 Winchester Ave | |
Entity Address, City or Town | New Haven | |
Entity Address, State or Province | CT | |
Entity Address, Postal Zip Code | 06511 | |
City Area Code | 203 | |
Local Phone Number | 535-1456 | |
Title of 12(b) Security | Common stock, par value $0.001 per share | |
Trading Symbol | ARVN | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 68,648,061 | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2024 | |
Document Fiscal Period Focus | Q2 | |
Entity Central Index Key | 0001655759 | |
Current Fiscal Year End Date | --12-31 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Current assets: | ||
Cash and cash equivalents | $ 154.8 | $ 311.7 |
Restricted cash | 5.5 | 5.5 |
Marketable securities | 1,073.9 | 949.3 |
Other receivables | 10 | 7.2 |
Prepaid expenses and other current assets | 12.5 | 6.5 |
Total current assets | 1,256.7 | 1,280.2 |
Property, equipment and leasehold improvements, net | 9.8 | 11.5 |
Operating lease right of use assets | 1.5 | 2.5 |
Collaboration contract asset and other assets | 11.6 | 10.4 |
Total assets | 1,279.6 | 1,304.6 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 78.1 | 92.2 |
Deferred revenue | 267.9 | 163 |
Current portion of operating lease liabilities | 1.2 | 1.9 |
Total current liabilities | 347.2 | 257.1 |
Deferred revenue | 331.3 | 386.2 |
Long term debt | 0.7 | 0.8 |
Operating lease liabilities | 0.2 | 0.5 |
Total liabilities | 679.4 | 644.6 |
Commitments and Contingencies (Note 13) | ||
Stockholders’ equity: | ||
Preferred stock, $0.001 par value, zero shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively | 0 | 0 |
Common stock, $0.001 par value; 68.6 and 68.0 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively | 0.1 | 0.1 |
Accumulated deficit | (1,437.3) | (1,332.7) |
Additional paid-in capital | 2,041.2 | 1,995.7 |
Accumulated other comprehensive loss | (3.8) | (3.1) |
Total stockholders’ equity | 600.2 | 660 |
Total liabilities and stockholders’ equity | $ 1,279.6 | $ 1,304.6 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares shares in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Statement of Financial Position [Abstract] | ||
Preferred stock par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares issued (in shares) | 68.6 | 68 |
Common stock, shares outstanding (in shares) | 68.6 | 68 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Income Statement [Abstract] | ||||
Revenue | $ 76.5 | $ 54.5 | $ 101.8 | $ 87 |
Operating expenses: | ||||
Research and development | 93.7 | 103.4 | 178 | 198.6 |
General and administrative | 31.3 | 25.7 | 55.6 | 50.7 |
Total operating expenses | 125 | 129.1 | 233.6 | 249.3 |
Loss from operations | (48.5) | (74.6) | (131.8) | (162.3) |
Other income (expense) | ||||
Other expense, net | (0.1) | 0 | (0.1) | (1.1) |
Interest income, net | 13.6 | 9 | 27.6 | 16.6 |
Total other income | 13.5 | 9 | 27.5 | 15.5 |
Net loss before income taxes and loss from equity method investment | (35) | (65.6) | (104.3) | (146.8) |
Income tax (expense) benefit | (0.2) | 0.3 | (0.3) | 0.7 |
Loss from equity method investment | 0 | (1.3) | 0 | (2.4) |
Net loss | $ (35.2) | $ (66.6) | $ (104.6) | $ (148.5) |
Net loss per common share, basic (in dollars per share) | $ (0.49) | $ (1.25) | $ (1.46) | $ (2.78) |
Net loss per common share, diluted (in dollars per share) | $ (0.49) | $ (1.25) | $ (1.46) | $ (2.78) |
Weighted average common shares outstanding, basic (in shares) | 71.9 | 53.4 | 71.7 | 53.4 |
Weighted average common shares outstanding, diluted (in shares) | 71.9 | 53.4 | 71.7 | 53.4 |
Condensed Consolidated Statements of Comprehensive Loss | ||||
Net loss | $ (35.2) | $ (66.6) | $ (104.6) | $ (148.5) |
Other comprehensive loss: | ||||
Unrealized gain (loss) on available-for-sale securities | 0.6 | 0.4 | (0.7) | 7 |
Comprehensive loss | $ (34.6) | $ (66.2) | $ (105.3) | $ (141.5) |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) - USD ($) shares in Millions, $ in Millions | Total | Common | Accumulated Deficit | Additional Paid-in Capital | Accumulated Other Comprehensive (Loss) Income |
Beginning balance (in shares) at Dec. 31, 2022 | 53.2 | ||||
Beginning balance at Dec. 31, 2022 | $ 564.9 | $ 0.1 | $ (965.4) | $ 1,549.4 | $ (19.2) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock-based compensation | 38.2 | 38.2 | |||
Net loss | (148.5) | (148.5) | |||
Issuance of common stock under equity incentive plans (in shares) | 0.2 | ||||
Issuance of common stock under equity incentive plans | 2 | 2 | |||
Unrealized gain (loss) on available-for-sale securities | 7 | 7 | |||
Ending balance (in shares) at Jun. 30, 2023 | 53.4 | ||||
Ending balance at Jun. 30, 2023 | 463.6 | $ 0.1 | (1,113.9) | 1,589.6 | (12.2) |
Beginning balance (in shares) at Mar. 31, 2023 | 53.4 | ||||
Beginning balance at Mar. 31, 2023 | 511 | $ 0.1 | (1,047.3) | 1,570.8 | (12.6) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock-based compensation | 18.3 | 18.3 | |||
Net loss | (66.6) | (66.6) | |||
Issuance of common stock under equity incentive plans | 0.5 | 0.5 | |||
Unrealized gain (loss) on available-for-sale securities | 0.4 | 0.4 | |||
Ending balance (in shares) at Jun. 30, 2023 | 53.4 | ||||
Ending balance at Jun. 30, 2023 | $ 463.6 | $ 0.1 | (1,113.9) | 1,589.6 | (12.2) |
Beginning balance (in shares) at Dec. 31, 2023 | 68 | 68 | |||
Beginning balance at Dec. 31, 2023 | $ 660 | $ 0.1 | (1,332.7) | 1,995.7 | (3.1) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock-based compensation | 40.2 | 40.2 | |||
Net loss | (104.6) | (104.6) | |||
Issuance of common stock under equity incentive plans (in shares) | 0.6 | ||||
Issuance of common stock under equity incentive plans | 5.3 | 5.3 | |||
Unrealized gain (loss) on available-for-sale securities | $ (0.7) | (0.7) | |||
Ending balance (in shares) at Jun. 30, 2024 | 68.6 | 68.6 | |||
Ending balance at Jun. 30, 2024 | $ 600.2 | $ 0.1 | (1,437.3) | 2,041.2 | (3.8) |
Beginning balance (in shares) at Mar. 31, 2024 | 68.3 | ||||
Beginning balance at Mar. 31, 2024 | 609.7 | $ 0.1 | (1,402.1) | 2,016.1 | (4.4) |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Stock-based compensation | 21.6 | 21.6 | |||
Net loss | (35.2) | (35.2) | |||
Issuance of common stock under equity incentive plans (in shares) | 0.3 | ||||
Issuance of common stock under equity incentive plans | 3.5 | 3.5 | |||
Unrealized gain (loss) on available-for-sale securities | $ 0.6 | 0.6 | |||
Ending balance (in shares) at Jun. 30, 2024 | 68.6 | 68.6 | |||
Ending balance at Jun. 30, 2024 | $ 600.2 | $ 0.1 | $ (1,437.3) | $ 2,041.2 | $ (3.8) |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Cash flows from operating activities: | ||
Net loss | $ (104.6) | $ (148.5) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 2.4 | 2.4 |
Net accretion of bond discounts/premiums | (11.2) | (7) |
Loss on sale of marketable securities | 0 | 0.9 |
Amortization of right-of-use assets | 1 | 0.9 |
Amortization of collaboration contract asset | 1.7 | 1.5 |
Stock-based compensation | 40.2 | 38.2 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 0 | 0.9 |
Other receivables | (2.8) | 2.4 |
Prepaid expenses and other current assets | (6) | 13.1 |
Collaboration contract asset | (3) | 0 |
Accounts payable and accrued liabilities | (13.9) | (0.6) |
Operating lease liability | (1) | (1) |
Deferred revenue | 50 | (83.1) |
Net cash used in operating activities | (47.2) | (179.9) |
Cash flows from investing activities: | ||
Purchases of marketable securities | (440.4) | (492.3) |
Maturities of marketable securities | 326.4 | 638.9 |
Sales of marketable securities | 0 | 42.3 |
Purchases of property, equipment and leasehold improvements | (0.8) | (1.7) |
Proceeds from disposal of property, equipment and leaseholds improvements | 0.1 | 0 |
Net cash (used in) provided by investing activities | (114.7) | 187.2 |
Cash flows from financing activities: | ||
Repayments of long term debt | (0.3) | 0 |
Proceeds from exercise of stock options and issuance of ESPP shares | 5.3 | 2 |
Net cash provided by financing activities | 5 | 2 |
Net (decrease) increase in cash, cash equivalents and restricted cash | (156.9) | 9.3 |
Cash, cash equivalents and restricted cash, beginning of the period | 317.2 | 86.8 |
Cash, cash equivalents and restricted cash, end of the period | 160.3 | 96.1 |
Supplemental disclosure of cash flow information: | ||
Purchases of property, equipment and leasehold improvements unpaid at period end | 0 | 0.4 |
Cash paid for taxes | $ 1.5 | $ 9 |
Nature of Business and Basis of
Nature of Business and Basis of Presentation | 6 Months Ended |
Jun. 30, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Business and Basis of Presentation | Nature of Business and Basis of Presentation Arvinas, Inc. and its subsidiaries (“Arvinas” or the "Company”) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (“Exchange Act”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (“SEC”) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December 31, 2023 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023, forming part of Arvinas’ 2023 Annual Report on Form 10-K filed with the SEC on February 27, 2024. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates. Risks and Uncertainties The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company’s products and to protect its proprietary technology. If the Company does not successfully obtain regulatory approval of its product candidates, it will be unable to generate revenue from product sales or achieve profitability. To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity interests, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents, restricted cash and marketable securities of approximately $1.2 billion as of June 30, 2024. |
Summary of Accounting Pronounce
Summary of Accounting Pronouncements and Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2024 | |
Accounting Policies [Abstract] | |
Summary of Accounting Pronouncements and Significant Accounting Policies | Summary of Accounting Pronouncements and Significant Accounting Policies Accounting Pronouncements Recently Adopted Accounting Pronouncements There have been no recently adopted accounting pronouncements that have had a material impact on the Company's unaudited condensed consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted Segment Reporting (Topic 280) - In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “ Segment Reporting - Improvements to Reportable Segment Disclosures, ” which requires disclosure of incremental segment information on an annual and interim basis and also requires companies with a single reportable segment to provide all disclosures required by this ASU and all existing segment disclosures in Accounting Standard Codification (“ASC”) 280, “ Segment Reporting .” The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures. Income Taxes (Topic 740) - In December 2023, the FASB issued ASU 2023-09, " Improvements to Income Tax Disclosures ," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on its related disclosures. Significant Accounting Policies There were no changes to the Company’s significant accounting policies during the six months ended June 30, 2024. Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023: (dollars in millions) June 30, June 30, Cash and cash equivalents $ 154.8 $ 90.6 Restricted cash 5.5 5.5 Cash, cash equivalents and restricted cash $ 160.3 $ 96.1 Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease as amended in August 2022. |
Research Collaboration and Lice
Research Collaboration and License Agreements | 6 Months Ended |
Jun. 30, 2024 | |
Research Collaboration And License Agreements [Abstract] | |
Research Collaboration and License Agreements | Research Collaboration and License Agreements Novartis License and Asset Agreements In April 2024, the Company entered into a transaction (the "Novartis Transaction"), including both a license agreement (the "Novartis License Agreement") and an asset purchase agreement (the "Novartis Asset Agreement") with Novartis Pharma AG ("Novartis") for the worldwide development, manufacture and commercialization of ARV-766, the Company's second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer and for the sale of the Company's preclinical AR-V7 program. Under the terms of the agreements, Novartis will be responsible for worldwide clinical development and commercialization of ARV-766 and will have all research, development, manufacturing, and commercialization rights with respect to the Company’s PROTAC® protein degrader targeting AR-V7, a splice variant of the AR. In May 2024, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired with respect to the Novartis Transaction (the “HSR Termination”). As a result of the HSR Termination and satisfaction of other closing conditions, Novartis paid to the Company a one-time, upfront payment in the aggregate amount of $150.0 million in accordance with the terms of the Novartis License Agreement and the Novartis Asset Agreement. Under the terms of the Novartis License Agreement, the Company is eligible to receive up to an additional $1.01 billion as contingent payments based on specified development, regulatory and commercial milestones for ARV-766 being met, as well as tiered royalties based on worldwide net sales of ARV-766, subject to reduction under certain circumstances as provided in the Novartis License Agreement. The Novartis License Agreement will expire on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue. The Company determined that the Novartis License Agreement and the Novartis Asset Agreement entered into with Novartis concurrently should be evaluated as a combined contract in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers . The Company determined the fair value of the assets sold under the Novartis Asset Agreement to be $20.0 million, which was recognized at the time of sale as revenue during the period ended June 30, 2024, and the fair value of the Novartis License Agreement to be $130.0 million, which is being recognized as revenue over the total estimated period of performance during the technology transfer period, as defined in the agreement, based on the cost incurred input method. Under the Novartis License Agreement, Novartis will also reimburse the Company for development costs incurred during the technology transfer period, which will be recognized as revenue as costs are incurred. As a direct result of the Company’s entry into the Novartis Transaction, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $3.0 million. In accordance with ASC 340, Other Assets and Deferred Costs , the Company recognized an asset of $3.0 million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the Novartis License Agreement and the Novartis Asset Agreement , which is being amortized as general and administrative expense over the total estimated period of performance under the Novartis License Agreement and the Novartis Asset Agreement . Vepdegestrant (ARV-471) Collaboration Agreement In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (“Pfizer”) (the “Vepdegestrant (ARV-471) Collaboration Agreement”) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company’s proprietary compound vepdegestrant (the “Licensed Products”). Under the Vepdegestrant (ARV-471) Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0 million. In addition, the Company is eligible to receive up to an additional $1.4 billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones. There were no regulatory or sales-based milestone payments received through June 30, 2024. The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing. As a direct result of the Company’s entry into the Vepdegestrant (ARV-471) Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9 million. In accordance with ASC 340, Other Assets and Deferred Costs , the Company recognized an asset of $12.9 million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the Vepdegestrant (ARV-471) Collaboration Agreement , which is being amortized as general and administrative expense over the total estimated period of performance under the Vepdegestrant (ARV-471) Collaboration Agreement. Bayer Collaboration Agreement In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the “Bayer Collaboration Agreement”) setting forth the Company’s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras ("PROTAC® targeted protein degraders") that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company’s technology license. The Company also received an additional $12.0 million from Bayer AG from inception through 2023, including $1.5 million received during the six months ended June 30, 2023. These payments are being recognized over the total estimated period of performance. The Company is also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated target proteins . In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. There were no development or sales-based milestone payments or royalties received through June 30, 2024. In June 2024, in accordance with the terms of the Bayer Collaboration Agreement, Bayer AG notified the Company of its intention to terminate the Bayer Collaboration Agreement, effective August 12, 2024. Pfizer Research Collaboration Agreement In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the “Pfizer Research Collaboration Agreement”). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company’s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all target proteins under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated target proteins under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. During the six months ended June 30, 2023, the Company received payments totaling $1.0 million for additional target proteins and services which are being recognized as revenue over the total period of performance. There were no sales-based milestone payments or royalties received through June 30, 2024. Restated Genentech Agreement In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the “Restated Genentech Agreement”) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Restated Genentech Agreement, the Company received additional upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the performance period. The Company is eligible to receive up to $44.0 million per target protein in development milestone payments, $52.5 million in regulatory milestone payments and $60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through June 30, 2024. Changes in the Company's contract balances for the six months ended June 30, 2024 and 2023 were as follows: (dollars in millions) June 30, June 30, Accounts receivable related to collaborations Beginning balance $ — $ 1.0 Additions 1.8 1.6 Payments received — (2.5) Ending balance $ 1.8 $ 0.1 Accounts payable related to collaborations Beginning balance $ 13.1 $ 5.0 Additions 29.2 1.7 Payments made (26.1) (6.7) Ending balance $ 16.2 $ — Contract assets: Collaboration contract asset Beginning balance $ 9.4 $ 10.7 Additions 3.0 — Amortization (1.7) (1.5) Ending balance $ 10.7 $ 9.2 Contract liabilities: Deferred revenue Beginning balance $ 549.2 $ 623.7 Additions to collaboration agreements 130.0 1.5 Revenue recognized from balances held at the beginning of the period (56.3) (84.6) Revenue recognized from new collaborations (23.7) — Ending balance $ 599.2 $ 540.6 During the six months ended June 30, 2023, the Company changed its estimate of the duration of the performance period under the Bayer Collaboration Agreement and Pfizer Research Collaboration Agreement as a result of updated research timelines. The changes in accounting estimate resulted in a decrease in revenue and net income of $8.2 million and a decrease in net loss per share of $0.15 for the six months ended June 30, 2023. The reversed revenue will be recognized in future periods as the Company continues to advance on the performance obligation under the updated collaboration timelines. During each of the three months ended June 30, 2024 and 2023 and the six months ended June 30, 2024, no changes in accounting estimates related to the Company's collaborations were recorded. The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of June 30, 2024 totaled $599.2 million, which is expected to be recognized in the following periods: (dollars in millions) Remainder of 2024 $ 191.2 2025 153.4 2026 105.0 2027 57.6 2028 59.8 2029 32.2 Total $ 599.2 |
Marketable Securities and Fair
Marketable Securities and Fair Value Measurements | 6 Months Ended |
Jun. 30, 2024 | |
Fair Value Disclosures [Abstract] | |
Marketable Securities and Fair Value Measurements | Marketable Securities and Fair Value Measurements The Company’s marketable securities consist of corporate bonds and government securities which are adjusted to fair value as of each balance sheet date based on quoted prices, which are considered Level 2 inputs. The following is a summary of the Company’s available-for-sale marketable securities measured at fair value on a recurring basis. June 30, 2024 (dollars in millions) Valuation Hierarchy Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate bonds Level 2 $ 1,069.0 $ — $ (3.8) $ 1,065.2 Government securities Level 2 8.7 — — 8.7 Total $ 1,077.7 $ — $ (3.8) $ 1,073.9 December 31, 2023 (dollars in millions) Valuation Hierarchy Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate bonds Level 2 $ 934.4 $ 1.5 $ (4.6) $ 931.3 Government securities Level 2 18.0 — — 18.0 Total $ 952.4 $ 1.5 $ (4.6) $ 949.3 The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature. The carrying values of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to the short-term nature of these assets and liabilities. |
Property, Equipment and Leaseho
Property, Equipment and Leasehold Improvements | 6 Months Ended |
Jun. 30, 2024 | |
Property, Plant and Equipment [Abstract] | |
Property, Equipment and Leasehold Improvements | Property, Equipment and Leasehold Improvements Property, equipment and leasehold improvements consist of the following: (dollars in millions) June 30, December 31, Laboratory equipment $ 18.9 $ 18.5 Leasehold improvements 11.7 11.5 Office equipment 2.6 2.6 Total property, equipment and leasehold improvements 33.2 32.6 Less: accumulated depreciation and amortization (23.4) (21.1) Property, equipment and leasehold improvements, net $ 9.8 $ 11.5 Depreciation and amortization expense totaled $1.2 million for each of the three months ended June 30, 2024 and 2023 and $2.4 million for each of the six months ended June 30, 2024 and 2023. |
Right-of-Use Assets and Liabili
Right-of-Use Assets and Liabilities | 6 Months Ended |
Jun. 30, 2024 | |
Leases [Abstract] | |
Right-of-Use Assets and Liabilities | Right-of-Use Assets and Liabilities The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets and operating lease liabilities in the condensed consolidated balance sheets. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments, which ranges from 3.0% - 7.5%. Lease expense is recognized on a straight-line basis over the lease term. The Company considers options to extend or terminate leases in recognizing ROU assets and lease liabilities when it is reasonably certain that such options will be exercised. In May 2021, the Company entered into a lease arrangement, which was amended in August 2022, for approximately 160,000 square feet of laboratory and office space, expected to be occupied in 2025. Once occupied, the base rent will range from $7.7 million to $8.8 million annually over a ten-year lease term. In connection with the signing and amendment of the lease, the Company issued a letter of credit totaling $5.5 million, collateralized by a certificate of deposit in the same amount, which is presented as restricted cash in the condensed consolidated balance sheets. The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than October 2025. The leases have a weighted average remaining term of one year. The components of lease expense were as follows: Three Months Ended Six Months Ended (dollars in millions) 2024 2023 2024 2023 Operating lease cost $ 0.5 $ 0.5 $ 1.0 $ 1.0 Supplemental cash flow information related to leases was as follows: Six Months Ended (dollars in millions) 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1.0 $ 1.0 Supplemental non-cash information: Right-of-use assets obtained in exchange for new lease obligations $ — $ — Maturities of operating lease liabilities as of June 30, 2024, were as follows: (dollars in millions) Remainder of 2024 $ 0.9 2025 0.5 Total lease payments 1.4 Less: imputed interest — Total $ 1.4 |
Accounts Payable and Accrued Li
Accounts Payable and Accrued Liabilities | 6 Months Ended |
Jun. 30, 2024 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Liabilities | Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consisted of the following: (dollars in millions) June 30, December 31, Accounts payable $ 23.2 $ 17.8 Accrued liabilities Research and development expenses 30.7 43.1 Employee expenses 16.0 25.7 Income taxes 3.4 0.7 Professional fees 2.7 2.5 General and administrative and commercial expenses 2.1 2.4 Total accounts payable and accrued liabilities $ 78.1 $ 92.2 |
Long-Term Debt
Long-Term Debt | 6 Months Ended |
Jun. 30, 2024 | |
Debt Disclosure [Abstract] | |
Long-Term Debt | Long-Term Debt Debt obligations consisted of the following: (dollars in millions) Maturity Date Interest Rate June 30, December 31, 2018 Assistance Agreement Debt 09/28 3.25% $ 0.9 $ 1.0 Less: current installments (0.2) (0.2) Total long-term debt $ 0.7 $ 0.8 In June 2018, the Company entered into an assistance agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028, with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received. Minimum future principal payments on long-term debt are as follows: (dollars in millions) Remainder of 2024 $ 0.1 2025 0.2 2026 0.2 2027 0.2 2028 0.2 Total $ 0.9 During the three and six months ended June 30, 2024 and 2023, interest expense was immaterial. |
Equity
Equity | 6 Months Ended |
Jun. 30, 2024 | |
Share-Based Payment Arrangement [Abstract] | |
Equity | Equity Equity Distribution Agreements In November 2023, the Company amended and restated the Equity Distribution Agreement with Piper Sandler & Company (“Piper Sandler”) and Cantor Fitzgerald & Co. (“Cantor”), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to approximately $262.8 million of the common stock registered under a universal shelf registration statement pursuant to one or more “at-the-market” offerings. During the six mo nths ended June 30, 2024, no shares were issued under this agreement. Stock-based Compensation 2018 Employee Stock Purchase Plan In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the “2018 ESPP”), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company’s common stock. The number of shares of the Company’s common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company’s then-outstanding common stock, effective as of January 1 of each year. As of June 30, 2024, 3,086,198 shares remained available for purchase. During the six months ended June 30, 2024 and 2023, the Company issued 34,515 and 23,206 shares of common stock, respectively, under the 2018 ESPP. 2018 Stock Incentive Plan In September 2018, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2018 Stock Incentive Plan (the “2018 Plan”), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company’s initial public offering. The number of shares of common stock initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Fourth Amendment to the Company’s Incentive Share Plan, which was terminated in September 2018, that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company’s common stock, 4% of the number of shares of the Company’s common stock outstanding on the first day of the year or an amount determined by the Company’s board of directors. As of June 30, 2024, 3,094,944 shares remained available for issuance under the 2018 Plan. Shares of common stock subject to outstanding equity awards that expire or are terminated, surrendered or canceled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards. Compensation Expense During the three months ended June 30, 2024 and 2023, the Company recognized compensation expense of $21.6 million and $18.3 million, respectively, related to the issuance of incentive awards, including $0.2 million and $0.3 million, respectively, related to the 2018 ESPP. During the six months ended June 30, 2024 and 2023, the Company recognized compensation expense of $40.2 million and $38.2 million, respectively, relating to the issuance of incentive awards, including $0.4 million and $0.5 million, respectively, related to the 2018 ESPP. As of June 30, 2024, there was $98.0 million of total unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately 1.4 years. Stock Options The fair value of the stock options granted during the six months ended June 30, 2024 and 2023 was determined using the Black-Scholes option pricing model with the following assumptions: June 30, June 30, Expected volatility (1) 72.9 - 75.6% 72.3 - 74.2% Expected term (years) (2) 5.4 - 5.5 5.5 - 7.0 Risk free interest rate (3) 3.9% - 4.6% 3.4% - 4.2% Expected dividend yield 0 % 0 % Exercise price $24.94 - $47.00 $23.23 - $36.27 (1) Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term. (2) Expected term is calculated based on the Company's historical experience. (3) Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant. A summary of the stock option activity during the six months ended June 30, 2024 is presented below. Included in the table are stock options granted to employees and directors under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). (dollars in millions, Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of December 31, 2023 7,933,794 $ 45.22 7.2 $ 62.6 Granted 1,107,366 $ 42.30 Exercised (221,719) $ 20.48 Forfeited (509,263) $ 56.47 Outstanding as of June 30, 2024 8,310,178 $ 44.83 7.1 $ 16.3 Vested and exercisable as of June 30, 2024 5,296,941 $ 44.61 6.2 $ 15.2 Vested and expected to vest as of June 30, 2024 8,025,590 $ 44.95 7.1 $ 16.1 The weighted-average grant date fair value per share of options granted during the six months ended June 30, 2024 and 2023 was $28.08 and $22.79, respectively. The total intrinsic value of options exercised during the six months ended June 30, 2024 and 2023 was $3.5 million and $0.6 million, respectively. Restricted Stock Units ("RSUs") A summary of RSU activity during the six months ended June 30, 2024 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). Shares Weighted Average Grant Date Fair Value Per Share Unvested RSUs as of December 31, 2023 1,151,856 $ 38.16 Granted 1,696,374 $ 44.98 Vested (263,531) $ 38.56 Forfeited (143,166) $ 42.62 Unvested RSUs as of June 30, 2024 2,441,533 $ 42.59 The total fair value of RSUs vested during the six months ended June 30, 2024 and 2023 was $10.2 million and $4.2 million, respectively. |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2024 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes For the three months ended June 30, 2024, the Company recognized income tax expense of $0.2 million, resulting in an effective tax rate of (0.6)%, as compared to income tax benefit $0.3 million, resulting in an effective tax rate of 0.4% in the same period for 2023. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended June 30, 2024 and the Company’s overall effective tax rate of (0.6)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended June 30, 2023 and the Company’s overall effective tax rate of 0.4% was the effect of expected benefits from state net operating loss carryback claims offset by equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. For the six months ended June 30, 2024, the Company recognized income tax expense of $0.3 million resulting in an effective tax rate of (0.3)%, as compared to income tax benefit of $0.7 million resulting in an effective tax rate of 0.4% in the same period for 2023. The primary reconciling items between the federal statutory rate of 21.0% for the six months ended June 30, 2024 and the Company’s overall effective tax rate of (0.3)% was the effect of equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the six months ended June 30, 2023 and the Company’s overall effective tax rate of 0.4% was the effect of expected benefits from state net operating loss carryback claims offset by equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. |
Net Loss Per Share
Net Loss Per Share | 6 Months Ended |
Jun. 30, 2024 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | Net Loss Per Share Basic and diluted loss per common share was calculated as follows: For the Three Months Ended For the Six Months Ended (dollars and shares in millions, except per share amounts) 2024 2023 2024 2023 Net loss $ (35.2) $ (66.6) $ (104.6) $ (148.5) Weighted average number of common shares outstanding - basic and diluted 71.9 53.4 71.7 53.4 Net loss per common share - basic and diluted $ (0.49) $ (1.25) $ (1.46) $ (2.78) The weighted average number of common shares included in the computation of basic and diluted net loss per common share for the three and six months ended June 30, 2024 gives effect to pre-funded warrants issued in November 2023 which allow holders to acquire up 3,422,380 shares of common stock at a nominal exercise price of $0.001 per share and are classified as equity. The shares underlying the pre-funded warrants are exercisable for little or no consideration and therefore the underlying shares are considered outstanding at the issuance of the pre-funded warrants for purposes of calculating the weighted average number of common shares outstanding in basic and diluted net loss per share for common share. The Company reported net losses for each of the three and six months ended June 30, 2024 and 2023, and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below: For the Three and Six Months Ended 2024 2023 Stock options 8.3 8.2 RSUs 2.4 1.1 10.7 9.3 |
Equity Method Investments
Equity Method Investments | 6 Months Ended |
Jun. 30, 2024 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Equity Method Investments | Equity Method Investments In July 2019, the Company and Bayer CropScience LP (“Bayer LP”) formed Oerth Bio LLC ("Oerth Bio"), a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. The Company and Bayer LP each held an initial ownership interest in Oerth Bio of 50%. A 15% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 44.5% and 45.5% as of June 30, 2024 and 2023, respectively, as a result of vested incentive units. Net loss of Oerth Bio for the three months ended June 30, 2024 and 2023 totaled $0.8 million and $2.8 million, respectively. The Company recognized equity method losses of zero and $1.3 million for the three months ended June 30, 2024 and 2023 , respectively. Net loss of Oerth Bio for the six months ended June 30, 2024 and 2023 totaled $1.5 million and $5.2 million , respectively. The Company recognized equity method losses of zero and $2.4 million for the six months ended June 30, 2024 and 2023 , respectively. As of June 30, 2024 and 2023 , the Company’s carrying value of t he investment was zero. The Company also provides Oerth Bio with compensated research, development and administrative services through a separate agreement. The services rendered by the Company during the three and six months ended June 30, 2024 and 2023 were immaterial. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2024 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred. The Company's accrual for such matters totaled $5.0 million and $10.0 million as of June 30, 2024 and 2023, respectively, related to the Amended License Agreement with Yale University ("Yale"), as further described below. Clinical and Preclinical Development and Licensing Arrangements From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice. In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known. Yale University License Agreement In June 2024, the Company entered into an Amended and Restated License Agreement (the “Amended License Agreement”) with Yale pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended to date (the "Original Agreement"). In connection with the signing of the Amended License Agreement, the Company made a payment of $14.95 million to Yale, comprising both an upfront payment connected to the Amended License Agreement and an amount related to the collaboration income under the Novartis License Agreement and Novartis Asset Agreement (see Note 3, Research Collaboration and License Agreements, for a description of the agreements ) . The Company will make another $5.0 million payment on the first anniversary of signing. Thereafter, the Company will also pay to Yale (1) up to $15.0 million if it secures approval of the first and second royalty products (as defined in the Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined “collaboration products,” and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined “meaningfully involved products.” The Company’s obligations under the Original Agreement to pay Yale minimum annual royalties and certain other annual fees have been eliminated and Yale has agreed to release all claims arising previously under the Original Agreement. Other provisions of the Original Agreement remain materially unchanged under the Amended License Agreement, including the requirement to pay to Yale a minimum license maintenance royalty totaling $0.1 million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately $3.0 million for the first licensed product and approximately $1.5 million for the second licensed product, certain of which milestones have already been satisfied, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $0.2 million to $0.5 million. FMI Agreement In June 2022, the Company entered into a Master In Vitro Diagnostics Agreement with Foundation Medicine, Inc. (the "FMI Agreement") for the development and commercialization of one or more of Foundation Medicine, Inc.’s companion in vitro diagnostic assays for use with one or more of the Company's therapeutic products. The FMI Agreement does not have a fixed duration, and the Company may terminate the FMI Agreement for convenience by providing adequate written notice to Foundation Medicine, Inc., subject to payment of applicable termination fees. Either party may terminate the FMI Agreement in its entirety for an uncured material breach by the other party, upon the bankruptcy or insolvency of the other party or by the mutual written agreement of both parties. Additionally, Foundation Medicine, Inc. may terminate the FMI Agreement with respect to an applicable program, (a) if a reasonably necessary third party license is not secured by Foundation Medicine, Inc. or if the Company does not consent to payments for such license, (b) if Foundation Medicine, Inc. reasonably determines that further development of the applicable assay is not technically feasible or (c) following a certain number of years after the first commercial launch of the applicable assay for use with the applicable therapeutic product. Certain licensing and other rights and certain obligations of Foundation Medicine, Inc. survive termination of the FMI Agreement. If the FMI Agreement is terminated in its entirety or with respect to any program, the Company has certain payment obligations remaining to Foundation Medicine, Inc. and may also be required to pay a termination fee, if applicable. ARV-766 In exchange for the development of FoundationOne® Liquid CDx as a companion diagnostic for use with ARV-766 for androgen receptor (“AR”) metastatic castration-resistant prostate cancer in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low tens of millions of dollars in addition to certain validation fees per sample and related pass-through costs. |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Pay vs Performance Disclosure | ||||
Net income (loss) | $ (35.2) | $ (66.6) | $ (104.6) | $ (148.5) |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Jun. 30, 2024 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Summary of Accounting Pronoun_2
Summary of Accounting Pronouncements and Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2024 | |
Accounting Policies [Abstract] | |
Basis of Presentation | The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (“Exchange Act”). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (“SEC”) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December 31, 2023 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023, forming part of Arvinas’ 2023 Annual Report on Form 10-K filed with the SEC on February 27, 2024. |
Use of Estimates | The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates. |
Risks and Uncertainties | Risks and Uncertainties |
Accounting Pronouncements | Accounting Pronouncements Recently Adopted Accounting Pronouncements There have been no recently adopted accounting pronouncements that have had a material impact on the Company's unaudited condensed consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted Segment Reporting (Topic 280) - In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “ Segment Reporting - Improvements to Reportable Segment Disclosures, ” which requires disclosure of incremental segment information on an annual and interim basis and also requires companies with a single reportable segment to provide all disclosures required by this ASU and all existing segment disclosures in Accounting Standard Codification (“ASC”) 280, “ Segment Reporting .” The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and disclosures. Income Taxes (Topic 740) - In December 2023, the FASB issued ASU 2023-09, " Improvements to Income Tax Disclosures ," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently in the process of evaluating the impact of this pronouncement on its related disclosures. |
Cash, Cash Equivalents and Restricted Cash | Cash, Cash Equivalents and Restricted Cash Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease as amended in August 2022. |
Summary of Accounting Pronoun_3
Summary of Accounting Pronouncements and Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Accounting Policies [Abstract] | |
Schedule of Cash and Cash Equivalents | The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023: (dollars in millions) June 30, June 30, Cash and cash equivalents $ 154.8 $ 90.6 Restricted cash 5.5 5.5 Cash, cash equivalents and restricted cash $ 160.3 $ 96.1 |
Schedule of Restrictions on Cash and Cash Equivalents | The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets to the total amounts shown in the condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023: (dollars in millions) June 30, June 30, Cash and cash equivalents $ 154.8 $ 90.6 Restricted cash 5.5 5.5 Cash, cash equivalents and restricted cash $ 160.3 $ 96.1 |
Research Collaboration and Li_2
Research Collaboration and License Agreements (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Research Collaboration And License Agreements [Abstract] | |
Schedule of Contract Balances | Changes in the Company's contract balances for the six months ended June 30, 2024 and 2023 were as follows: (dollars in millions) June 30, June 30, Accounts receivable related to collaborations Beginning balance $ — $ 1.0 Additions 1.8 1.6 Payments received — (2.5) Ending balance $ 1.8 $ 0.1 Accounts payable related to collaborations Beginning balance $ 13.1 $ 5.0 Additions 29.2 1.7 Payments made (26.1) (6.7) Ending balance $ 16.2 $ — Contract assets: Collaboration contract asset Beginning balance $ 9.4 $ 10.7 Additions 3.0 — Amortization (1.7) (1.5) Ending balance $ 10.7 $ 9.2 Contract liabilities: Deferred revenue Beginning balance $ 549.2 $ 623.7 Additions to collaboration agreements 130.0 1.5 Revenue recognized from balances held at the beginning of the period (56.3) (84.6) Revenue recognized from new collaborations (23.7) — Ending balance $ 599.2 $ 540.6 |
Schedule of Transaction Price Allocated to Performance Obligations | The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of June 30, 2024 totaled $599.2 million, which is expected to be recognized in the following periods: (dollars in millions) Remainder of 2024 $ 191.2 2025 153.4 2026 105.0 2027 57.6 2028 59.8 2029 32.2 Total $ 599.2 |
Marketable Securities and Fai_2
Marketable Securities and Fair Value Measurements (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Fair Value Disclosures [Abstract] | |
Schedule of Available-for-Sale Marketable Securities | The following is a summary of the Company’s available-for-sale marketable securities measured at fair value on a recurring basis. June 30, 2024 (dollars in millions) Valuation Hierarchy Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate bonds Level 2 $ 1,069.0 $ — $ (3.8) $ 1,065.2 Government securities Level 2 8.7 — — 8.7 Total $ 1,077.7 $ — $ (3.8) $ 1,073.9 December 31, 2023 (dollars in millions) Valuation Hierarchy Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Corporate bonds Level 2 $ 934.4 $ 1.5 $ (4.6) $ 931.3 Government securities Level 2 18.0 — — 18.0 Total $ 952.4 $ 1.5 $ (4.6) $ 949.3 |
Property, Equipment and Lease_2
Property, Equipment and Leasehold Improvements (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Property, Plant and Equipment [Abstract] | |
Schedule of Property, Equipment and Leasehold Improvements | Property, equipment and leasehold improvements consist of the following: (dollars in millions) June 30, December 31, Laboratory equipment $ 18.9 $ 18.5 Leasehold improvements 11.7 11.5 Office equipment 2.6 2.6 Total property, equipment and leasehold improvements 33.2 32.6 Less: accumulated depreciation and amortization (23.4) (21.1) Property, equipment and leasehold improvements, net $ 9.8 $ 11.5 |
Right-of-Use Assets and Liabi_2
Right-of-Use Assets and Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Leases [Abstract] | |
Schedule of Components of Lease Expense | The components of lease expense were as follows: Three Months Ended Six Months Ended (dollars in millions) 2024 2023 2024 2023 Operating lease cost $ 0.5 $ 0.5 $ 1.0 $ 1.0 |
Schedule of Supplemental Cash Flow Information Related to Leases | Supplemental cash flow information related to leases was as follows: Six Months Ended (dollars in millions) 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 1.0 $ 1.0 Supplemental non-cash information: Right-of-use assets obtained in exchange for new lease obligations $ — $ — |
Schedule of Maturities of Operating Lease Liabilities | Maturities of operating lease liabilities as of June 30, 2024, were as follows: (dollars in millions) Remainder of 2024 $ 0.9 2025 0.5 Total lease payments 1.4 Less: imputed interest — Total $ 1.4 |
Accounts Payable and Accrued _2
Accounts Payable and Accrued Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Payables and Accruals [Abstract] | |
Schedule of Components of Accounts Payable and Accrued Liabilities | Accounts payable and accrued liabilities consisted of the following: (dollars in millions) June 30, December 31, Accounts payable $ 23.2 $ 17.8 Accrued liabilities Research and development expenses 30.7 43.1 Employee expenses 16.0 25.7 Income taxes 3.4 0.7 Professional fees 2.7 2.5 General and administrative and commercial expenses 2.1 2.4 Total accounts payable and accrued liabilities $ 78.1 $ 92.2 |
Long-Term Debt (Tables)
Long-Term Debt (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Debt Disclosure [Abstract] | |
Schedule of Long-Term Debt | Debt obligations consisted of the following: (dollars in millions) Maturity Date Interest Rate June 30, December 31, 2018 Assistance Agreement Debt 09/28 3.25% $ 0.9 $ 1.0 Less: current installments (0.2) (0.2) Total long-term debt $ 0.7 $ 0.8 |
Schedule of Minimum Future Payments on Long-Term Debt | Minimum future principal payments on long-term debt are as follows: (dollars in millions) Remainder of 2024 $ 0.1 2025 0.2 2026 0.2 2027 0.2 2028 0.2 Total $ 0.9 |
Equity (Tables)
Equity (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted | The fair value of the stock options granted during the six months ended June 30, 2024 and 2023 was determined using the Black-Scholes option pricing model with the following assumptions: June 30, June 30, Expected volatility (1) 72.9 - 75.6% 72.3 - 74.2% Expected term (years) (2) 5.4 - 5.5 5.5 - 7.0 Risk free interest rate (3) 3.9% - 4.6% 3.4% - 4.2% Expected dividend yield 0 % 0 % Exercise price $24.94 - $47.00 $23.23 - $36.27 (1) Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term. (2) Expected term is calculated based on the Company's historical experience. (3) Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant. |
Schedule of Stock Option Activity | A summary of the stock option activity during the six months ended June 30, 2024 is presented below. Included in the table are stock options granted to employees and directors under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). (dollars in millions, Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding as of December 31, 2023 7,933,794 $ 45.22 7.2 $ 62.6 Granted 1,107,366 $ 42.30 Exercised (221,719) $ 20.48 Forfeited (509,263) $ 56.47 Outstanding as of June 30, 2024 8,310,178 $ 44.83 7.1 $ 16.3 Vested and exercisable as of June 30, 2024 5,296,941 $ 44.61 6.2 $ 15.2 Vested and expected to vest as of June 30, 2024 8,025,590 $ 44.95 7.1 $ 16.1 |
Schedule of Restricted Stock Grant Activity | A summary of RSU activity during the six months ended June 30, 2024 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4). Shares Weighted Average Grant Date Fair Value Per Share Unvested RSUs as of December 31, 2023 1,151,856 $ 38.16 Granted 1,696,374 $ 44.98 Vested (263,531) $ 38.56 Forfeited (143,166) $ 42.62 Unvested RSUs as of June 30, 2024 2,441,533 $ 42.59 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Earnings Per Share [Abstract] | |
Schedule of Basic and Diluted Loss per Common Share | Basic and diluted loss per common share was calculated as follows: For the Three Months Ended For the Six Months Ended (dollars and shares in millions, except per share amounts) 2024 2023 2024 2023 Net loss $ (35.2) $ (66.6) $ (104.6) $ (148.5) Weighted average number of common shares outstanding - basic and diluted 71.9 53.4 71.7 53.4 Net loss per common share - basic and diluted $ (0.49) $ (1.25) $ (1.46) $ (2.78) |
Schedule of Securities Excluded From Computation of Diluted Net Loss Per Common Share | The Company reported net losses for each of the three and six months ended June 30, 2024 and 2023, and therefore excluded all stock options and RSUs from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below: For the Three and Six Months Ended 2024 2023 Stock options 8.3 8.2 RSUs 2.4 1.1 10.7 9.3 |
Nature of Business and Basis _2
Nature of Business and Basis of Presentation (Details) $ in Billions | Jun. 30, 2024 USD ($) |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Cash, cash equivalents, restricted cash and marketable securities | $ 1.2 |
Summary of Accounting Pronoun_4
Summary of Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 | Jun. 30, 2023 | Dec. 31, 2022 |
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 154.8 | $ 311.7 | $ 90.6 | |
Restricted cash | 5.5 | 5.5 | 5.5 | |
Cash, cash equivalents and restricted cash | $ 160.3 | $ 317.2 | $ 96.1 | $ 86.8 |
Research Collaboration and Li_3
Research Collaboration and License Agreements - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | 35 Months Ended | ||||||||
Nov. 30, 2017 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2018 | Jun. 30, 2024 | May 31, 2024 | Apr. 30, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Jul. 31, 2021 | Jun. 30, 2019 | |
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract with customer, liability | $ 599,200,000 | $ 540,600,000 | $ 599,200,000 | $ 540,600,000 | $ 599,200,000 | $ 549,200,000 | $ 623,700,000 | ||||||
Revenue, remaining performance obligation | 599,200,000 | 599,200,000 | 599,200,000 | ||||||||||
Contract revenue receivable if milestones achieved | 10,700,000 | 9,200,000 | 10,700,000 | 9,200,000 | 10,700,000 | 9,400,000 | $ 10,700,000 | ||||||
Collaboration contract asset and other assets | 11,600,000 | 11,600,000 | 11,600,000 | 10,400,000 | |||||||||
Revenue | 76,500,000 | 54,500,000 | 101,800,000 | 87,000,000 | |||||||||
Net income (loss) | $ (35,200,000) | $ (66,600,000) | $ (104,600,000) | $ (148,500,000) | |||||||||
Net loss per common share, basic (in dollars per share) | $ (0.49) | $ (1.25) | $ (1.46) | $ (2.78) | |||||||||
Net loss per common share, diluted (in dollars per share) | $ (0.49) | $ (1.25) | $ (1.46) | $ (2.78) | |||||||||
Updated Research Timelines | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Revenue | $ (8,200,000) | ||||||||||||
Net income (loss) | $ (8,200,000) | ||||||||||||
Net loss per common share, basic (in dollars per share) | $ (0.15) | ||||||||||||
Net loss per common share, diluted (in dollars per share) | $ (0.15) | ||||||||||||
Novartis Pharma AG | License | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract with customer, liability | $ 150,000,000 | ||||||||||||
Contingent payments | $ 1,010,000,000 | ||||||||||||
Revenue recognized | $ 20,000,000 | ||||||||||||
Revenue, remaining performance obligation | 130,000,000 | $ 130,000,000 | 130,000,000 | ||||||||||
Capitalized costs | $ 3,000,000 | ||||||||||||
Pfizer, Inc. | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Payments received | $ 1,000,000 | $ 28,000,000 | |||||||||||
Pfizer, Inc. | Collaboration Agreement | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | $ 650,000,000 | ||||||||||||
Collaboration agreement direct and incremental costs incurred | 12,900,000 | ||||||||||||
Collaboration contract asset and other assets | 12,900,000 | 12,900,000 | 12,900,000 | ||||||||||
Pfizer, Inc. | Regulatory and Sales-Based Milestones | Maximum | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | 1,400,000,000 | ||||||||||||
Pfizer, Inc. | Regulatory Milestone Related to Marketing Approvals | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | 400,000,000 | ||||||||||||
Payments received | 0 | ||||||||||||
Pfizer, Inc. | Sales-Based Milestones | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | $ 1,000,000,000 | ||||||||||||
Pfizer, Inc. | Development Milestone Payments | Maximum | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | 225,000,000 | 225,000,000 | 225,000,000 | ||||||||||
Pfizer, Inc. | Sales Based Milestone Payments | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Payments received | 0 | 0 | |||||||||||
Pfizer, Inc. | Sales Based Milestone Payments | Maximum | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | 550,000,000 | 550,000,000 | 550,000,000 | ||||||||||
Pfizer, Inc. | Option Payments To License Agreement | Maximum | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | 37,500,000 | 37,500,000 | 37,500,000 | ||||||||||
Bayer Collaboration Agreement | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | $ 17,500,000 | ||||||||||||
Bayer Collaboration Agreement | Research Funding Payments | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | $ 12,000,000 | ||||||||||||
Payments received | $ 1,500,000 | ||||||||||||
Bayer Collaboration Agreement | Development Milestone Payments | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Payments received | 0 | ||||||||||||
Bayer Collaboration Agreement | Development Milestone Payments | Maximum | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | 197,500,000 | ||||||||||||
Bayer Collaboration Agreement | Sales Based Milestone Payments | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Payments received | 0 | ||||||||||||
Bayer Collaboration Agreement | Sales Based Milestone Payments | Maximum | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | $ 490,000,000 | ||||||||||||
Genentech | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Payments received | $ 34,500,000 | ||||||||||||
Additional upfront non-refundable amount received under previous agreement | $ 11,000,000 | ||||||||||||
Genentech | Regulatory Milestone Related to Marketing Approvals | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | 52,500,000 | 52,500,000 | 52,500,000 | ||||||||||
Genentech | Development Milestone Payments | Maximum | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | 44,000,000 | 44,000,000 | 44,000,000 | ||||||||||
Genentech | Commercial Milestones | |||||||||||||
Research Collaboration And License Agreements [Line Items] | |||||||||||||
Contract revenue receivable if milestones achieved | $ 60,000,000 | 60,000,000 | $ 60,000,000 | ||||||||||
Payments received | $ 0 |
Research Collaboration and Li_4
Research Collaboration and License Agreements - Summary of Contract Balances (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Accounts receivable related to collaborations | ||
Beginning balance | $ 0 | $ 1 |
Additions | 1.8 | 1.6 |
Payments received | 0 | (2.5) |
Ending balance | 1.8 | 0.1 |
Accounts payable related to collaborations | ||
Beginning balance | 13.1 | 5 |
Additions | 29.2 | 1.7 |
Payments made | (26.1) | (6.7) |
Ending balance | 16.2 | 0 |
Contract assets: Collaboration contract asset | ||
Beginning balance | 9.4 | 10.7 |
Additions | 3 | 0 |
Amortization | (1.7) | (1.5) |
Ending balance | 10.7 | 9.2 |
Contract liabilities: Deferred revenue | ||
Beginning balance | 549.2 | 623.7 |
Additions to collaboration agreements | 130 | 1.5 |
Revenue recognized from balances held at the beginning of the period | (56.3) | (84.6) |
Revenue recognized from new collaborations | (23.7) | 0 |
Ending balance | $ 599.2 | $ 540.6 |
Research Collaboration and Li_5
Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details) $ in Millions | Jun. 30, 2024 USD ($) |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | $ 599.2 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-07-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | $ 191.2 |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 6 months |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | $ 153.4 |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2026-01-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | $ 105 |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2027-01-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | $ 57.6 |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2028-01-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | $ 59.8 |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2029-01-01 | |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] | |
Revenue, remaining performance obligation | $ 32.2 |
Revenue, remaining performance obligation, expected timing of satisfaction, period | 1 year |
Marketable Securities and Fai_3
Marketable Securities and Fair Value Measurements (Details) - Level 2 - Fair Value, Measurements, Recurring - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | $ 1,077.7 | $ 952.4 |
Gross Unrealized Gains | 0 | 1.5 |
Gross Unrealized Losses | (3.8) | (4.6) |
Fair Value | 1,073.9 | 949.3 |
Corporate bonds | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | 1,069 | 934.4 |
Gross Unrealized Gains | 0 | 1.5 |
Gross Unrealized Losses | (3.8) | (4.6) |
Fair Value | 1,065.2 | 931.3 |
Government securities | ||
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] | ||
Amortized Cost | 8.7 | 18 |
Gross Unrealized Gains | 0 | 0 |
Gross Unrealized Losses | 0 | 0 |
Fair Value | $ 8.7 | $ 18 |
Property, Equipment and Lease_3
Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Property Plant And Equipment [Line Items] | ||
Total property, equipment and leasehold improvements | $ 33.2 | $ 32.6 |
Less: accumulated depreciation and amortization | (23.4) | (21.1) |
Property, equipment and leasehold improvements, net | 9.8 | 11.5 |
Laboratory equipment | ||
Property Plant And Equipment [Line Items] | ||
Total property, equipment and leasehold improvements | 18.9 | 18.5 |
Leasehold improvements | ||
Property Plant And Equipment [Line Items] | ||
Total property, equipment and leasehold improvements | 11.7 | 11.5 |
Office equipment | ||
Property Plant And Equipment [Line Items] | ||
Total property, equipment and leasehold improvements | $ 2.6 | $ 2.6 |
Property, Equipment and Lease_4
Property, Equipment and Leasehold Improvements - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Property, Plant and Equipment [Abstract] | ||||
Depreciation and amortization expense | $ 1.2 | $ 1.2 | $ 2.4 | $ 2.4 |
Right-of-Use Assets and Liabi_3
Right-of-Use Assets and Liabilities - Additional Information (Details) ft² in Thousands, $ in Millions | 1 Months Ended | |
May 31, 2021 USD ($) ft² | Jun. 30, 2024 USD ($) | |
Lessee Lease Description [Line Items] | ||
Lease for laboratory and office space (in sq feet) | ft² | 160 | |
Base rent lease term (in years) | 10 years | |
Operating lease, weighted average remaining lease term (in years) | 1 year | |
Letter of Credit | Asset Pledged as Collateral | ||
Lessee Lease Description [Line Items] | ||
Letter of credit for collateralized by certificate of deposit | $ 5.5 | |
Minimum | ||
Lessee Lease Description [Line Items] | ||
Percentage of incremental borrowing for lease payments | 3% | |
Base rent | $ 7.7 | |
Maximum | ||
Lessee Lease Description [Line Items] | ||
Percentage of incremental borrowing for lease payments | 7.50% | |
Base rent | $ 8.8 |
Right-of-Use Assets and Liabi_4
Right-of-Use Assets and Liabilities - Components of Lease Expense (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Leases [Abstract] | ||||
Operating lease cost | $ 0.5 | $ 0.5 | $ 1 | $ 1 |
Right-of-Use Assets and Liabi_5
Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Cash paid for amounts included in the measurement of lease liabilities: | ||
Operating cash flows from operating leases | $ 1 | $ 1 |
Supplemental non-cash information: | ||
Right-of-use assets obtained in exchange for new lease obligations | $ 0 | $ 0 |
Right-of-Use Assets and Liabi_6
Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Millions | Jun. 30, 2024 USD ($) |
Leases [Abstract] | |
Remainder of 2024 | $ 0.9 |
2025 | 0.5 |
Total lease payments | 1.4 |
Less: imputed interest | 0 |
Total | $ 1.4 |
Accounts Payable and Accrued _3
Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Payables and Accruals [Abstract] | ||
Accounts payable | $ 23.2 | $ 17.8 |
Accrued liabilities | ||
Research and development expenses | 30.7 | 43.1 |
Employee expenses | 16 | 25.7 |
Income taxes | 3.4 | 0.7 |
Professional fees | 2.7 | 2.5 |
General and administrative and commercial expenses | 2.1 | 2.4 |
Total accounts payable and accrued liabilities | $ 78.1 | $ 92.2 |
Long-Term Debt - Schedule of Lo
Long-Term Debt - Schedule of Long Term Debt (Details) - USD ($) $ in Millions | Jun. 30, 2024 | Dec. 31, 2023 |
Debt Instrument [Line Items] | ||
Total | $ 0.9 | |
Less: current installments | (0.2) | $ (0.2) |
Total long-term debt | $ 0.7 | 0.8 |
2018 Assistance Agreement | ||
Debt Instrument [Line Items] | ||
Interest Rate | 3.25% | |
Total | $ 0.9 | $ 1 |
Long-Term Debt - Additional Inf
Long-Term Debt - Additional Information (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||
Sep. 30, 2018 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Debt Instrument [Line Items] | |||||
Interest expense | $ 0 | $ 0 | $ 0 | $ 0 | |
2018 Assistance Agreement | |||||
Debt Instrument [Line Items] | |||||
Debt instrument bearing interest rate | 3.25% | 3.25% | |||
2018 Assistance Agreement | State of Connecticut | |||||
Debt Instrument [Line Items] | |||||
Debt instrument face amount | $ 2 | ||||
Loan forgiveness | $ 1 | ||||
Debt instrument bearing interest rate | 3.25% | ||||
Debt instrument interest payments term (in months) | 60 months | ||||
Percentage of liquidated damages | 7.50% |
Long-Term Debt - Schedule of Mi
Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details) $ in Millions | Jun. 30, 2024 USD ($) |
Debt Disclosure [Abstract] | |
Remainder of 2024 | $ 0.1 |
2025 | 0.2 |
2026 | 0.2 |
2027 | 0.2 |
2028 | 0.2 |
Total | $ 0.9 |
Equity - Additional Information
Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Sep. 30, 2018 | Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2019 | Nov. 30, 2023 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Compensation expense | $ 21.6 | $ 18.3 | |||||
Inducement grants (in shares) | 255,611 | ||||||
Weighted-average grant date fair value of options (in dollars per share) | $ 28.08 | $ 22.79 | |||||
Intrinsic value of options exercised | $ 3.5 | $ 0.6 | |||||
2018 ESPP | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Common stock reserved for issuance (in shares) | 311,850 | ||||||
Common stock reserved for issuance represented as percentage on outstanding common stock | 1% | ||||||
Common stock, shares remained available for purchase (in shares) | 3,086,198 | 3,086,198 | |||||
Common stock, shares issued (in shares) | 34,515 | 23,206 | |||||
RSUs | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Number of inducement grants (in shares) | 170,365 | ||||||
Total fair value of RSUs vested | $ 10.2 | $ 4.2 | |||||
2018 Plan | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Common stock reserved for issuance (in shares) | 4,067,007 | ||||||
Common stock, shares remained available for purchase (in shares) | 3,094,944 | 3,094,944 | |||||
Annual increase in reserved shares as percentage of outstanding common stock | 4% | ||||||
Compensation expense | $ 0.2 | $ 0.3 | |||||
2018 Plan | Minimum | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Annual increase in reserved shares of common stock (in shares) | 4,989,593 | ||||||
Incentive Plan | Employees | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Compensation expense | $ 40.2 | 38.2 | |||||
Incentive Plan | Employees | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Compensation expense not yet recognized | $ 98 | $ 98 | |||||
Compensation expense not yet recognized, period of recognition (in years) | 1 year 4 months 24 days | ||||||
Incentive Plan | Maximum | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Common stock reserved for issuance (in shares) | 1,277,181 | ||||||
2018 ESPP | Incentive Plan | Employees | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Compensation expense | $ 0.4 | $ 0.5 | |||||
Piper Sandler and Cantor | At-the-Market Offering | Equity Distribution Agreement | |||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | |||||||
Common stock aggregate offering price | $ 262.8 | ||||||
Common stock issued, net of issuance costs (in shares) | 0 |
Equity - Schedule of Assumption
Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details) - Stock options - $ / shares | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected volatility, minimum (percentage) | 72.90% | 72.30% |
Expected volatility, maximum (percentage) | 75.60% | 74.20% |
Risk free interest rate, minimum (percentage) | 3.90% | 3.40% |
Risk free interest rate, maximum (percentage) | 4.60% | 4.20% |
Expected dividend yield (percentage) | 0% | 0% |
Minimum | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected term (years) | 5 years 4 months 24 days | 5 years 6 months |
Exercise price (in usd per share) | $ 24.94 | $ 23.23 |
Maximum | ||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||
Expected term (years) | 5 years 6 months | 7 years |
Exercise price (in usd per share) | $ 47 | $ 36.27 |
Equity - Summary of Stock Optio
Equity - Summary of Stock Option Activity (Details) - 2018 Plan - USD ($) $ / shares in Units, $ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2024 | Dec. 31, 2023 | |
Options | ||
Beginning balance (in shares) | 7,933,794 | |
Granted (in shares) | 1,107,366 | |
Exercised (in shares) | (221,719) | |
Forfeited (in shares) | (509,263) | |
Ending balance (in shares) | 8,310,178 | 7,933,794 |
Vested and exercisable, ending balance (in shares) | 5,296,941 | |
Vested and expected to vest (in shares) | 8,025,590 | |
Weighted Average Exercise Price | ||
Beginning balance (in dollars per share) | $ 45.22 | |
Granted (in dollars per share) | 42.30 | |
Exercised (in dollars per share) | 20.48 | |
Forfeited (in dollars per share) | 56.47 | |
Ending balance (in dollars per share) | 44.83 | $ 45.22 |
Vested and exercisable (in dollars per share) | 44.61 | |
Vested and expected to vest (in dollars per share) | $ 44.95 | |
Weighted Average Remaining Contractual Term (Years) | ||
Outstanding (in years) | 7 years 1 month 6 days | 7 years 2 months 12 days |
Vested and exercisable (in years) | 6 years 2 months 12 days | |
Vested and expected to vest (in Years) | 7 years 1 month 6 days | |
Aggregate Intrinsic Value | ||
Outstanding | $ 16.3 | $ 62.6 |
Vested and exercisable | 15.2 | |
Vested and expected to vest | $ 16.1 |
Equity - Summary of Restricted
Equity - Summary of Restricted Stock (Details) - 2018 Plan - RSUs - Employees | 6 Months Ended |
Jun. 30, 2024 $ / shares shares | |
Shares | |
Beginning balance (in shares) | shares | 1,151,856 |
Granted (in shares) | shares | 1,696,374 |
Vested (in shares) | shares | (263,531) |
Forfeited (in shares) | shares | (143,166) |
Ending balance (in shares) | shares | 2,441,533 |
Weighted Average Grant Date Fair Value Per Share | |
Beginning balance (in dollars per share) | $ / shares | $ 38.16 |
Granted (in dollars per share) | $ / shares | 44.98 |
Vested (in dollars per share) | $ / shares | 38.56 |
Forfeited (in dollars per share) | $ / shares | 42.62 |
Ending balance (in dollars per share) | $ / shares | $ 42.59 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Income Tax Disclosure [Abstract] | ||||
Income tax (expense) benefit | $ (0.2) | $ 0.3 | $ (0.3) | $ 0.7 |
Effective tax rate | (0.60%) | 0.40% | (0.30%) | 0.40% |
Federal statutory rate, percentage | 21% | 21% | 21% | 21% |
Net Loss Per Share - Basic and
Net Loss Per Share - Basic and Diluted Loss per Common Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Earnings Per Share [Abstract] | ||||
Net loss | $ (35.2) | $ (66.6) | $ (104.6) | $ (148.5) |
Weighted average number of common shares outstanding, basic (in shares) | 71.9 | 53.4 | 71.7 | 53.4 |
Weighted average number of common shares outstanding, diluted (in shares) | 71.9 | 53.4 | 71.7 | 53.4 |
Net loss per common share - basic (in dollars per share) | $ (0.49) | $ (1.25) | $ (1.46) | $ (2.78) |
Net loss per common share - diluted (in dollars per share) | $ (0.49) | $ (1.25) | $ (1.46) | $ (2.78) |
Net Loss Per Share - Additional
Net Loss Per Share - Additional Information (Details) - Pre-Funded Warrant | Nov. 30, 2023 $ / shares shares |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | |
Warrants to be purchased (in shares) | shares | 3,422,380 |
Warrant exercise price (in usd per share) | $ / shares | $ 0.001 |
Net Loss Per Share - Securities
Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details) - shares shares in Millions | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of diluted net loss per common share (in shares) | 10.7 | 9.3 | 10.7 | 9.3 |
Stock options | ||||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of diluted net loss per common share (in shares) | 8.3 | 8.2 | 8.3 | 8.2 |
RSUs | ||||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of diluted net loss per common share (in shares) | 2.4 | 1.1 | 2.4 | 1.1 |
Equity Method Investments (Deta
Equity Method Investments (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Jul. 31, 2019 | |
Schedule Of Equity Method Investments [Line Items] | |||||
Net loss | $ (35,200,000) | $ (66,600,000) | $ (104,600,000) | $ (148,500,000) | |
Loss from equity method investment | 0 | 1,300,000 | 0 | 2,400,000 | |
Oerth | |||||
Schedule Of Equity Method Investments [Line Items] | |||||
Future grant of incentive units to service providers percentage | 15% | ||||
Loss from equity method investment | 0 | 1,300,000 | 0 | 2,400,000 | |
Equity method investments | 0 | 0 | 0 | 0 | |
Oerth | |||||
Schedule Of Equity Method Investments [Line Items] | |||||
Net loss | $ (800,000) | $ (2,800,000) | $ (1,500,000) | $ (5,200,000) | |
Bayer LP | Oerth | |||||
Schedule Of Equity Method Investments [Line Items] | |||||
Ownership interest, percentage | 44.50% | 45.50% | 44.50% | 45.50% | 50% |
Commitments and Contingencies (
Commitments and Contingencies (Details) $ in Thousands | 1 Months Ended | |||
Jun. 04, 2022 USD ($) | Jul. 05, 2013 USD ($) product | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | |
Commitments And Contingencies [Line Items] | ||||
Loss contingency | $ 5,000 | $ 10,000 | ||
Yale University | Maximum | ||||
Commitments And Contingencies [Line Items] | ||||
Royalty payment | $ 500 | |||
Yale University | Minimum | ||||
Commitments And Contingencies [Line Items] | ||||
Annual payment for license | $ 100 | |||
Number of licensed products | product | 2 | |||
Royalty payment | $ 200 | |||
Yale University | Upfront Payment for Amended License Agreement and Novartis License and Asset Agreements | ||||
Commitments And Contingencies [Line Items] | ||||
Payments for collaboration | 14,950 | |||
Yale University | Milestone Payment on First Anniversary of Signing | ||||
Commitments And Contingencies [Line Items] | ||||
Milestone payment the Company will make | 5,000 | |||
Yale University | Milestone Payment Upon Approval of First and Second Royalty Products | Maximum | ||||
Commitments And Contingencies [Line Items] | ||||
Milestone payment the Company will make | $ 15,000 | |||
Yale University | Success-Based Milestone Payments | License First Licensed Product | ||||
Commitments And Contingencies [Line Items] | ||||
Required milestone payments | 3,000 | |||
Yale University | Success-Based Milestone Payments | License Second Licensed Product | ||||
Commitments And Contingencies [Line Items] | ||||
Required milestone payments | $ 1,500 | |||
Foundation Medicine, Inc. | Success-Based Milestone Payments | Maximum | ||||
Commitments And Contingencies [Line Items] | ||||
Milestone payments the Company is entitled to (up to) | $ 10,000 |